GU CONNECT has summarised the highlights of the recent congress of the American Society of Clinical Oncology GU (ASCO GU) 2017 in Orlando, USA for you
Prostate Cancer by Asst. Prof. Alicia Morgans
GU CONNECT has summarised the highlights of the recent congress of the American Society of Clinical Oncology GU (ASCO GU) 2017 in Orlando, USA for you
Prostate Cancer by Asst. Prof. Alicia Morgans
Dr Morgans is Genitourinary Medical Oncologist at Dana-Farber Cancer Institute, and Faculty in Medicine at Harvard Medical School in Boston, MA. She completed medical school and residency at the University of Pennsylvania School of Medicine, fellowship in Hematology/Oncology at Harvard’s Dana Farber Cancer Institute and Massachusetts General Hospital Cancer Center in Boston and earned a Master of Public Health at Vanderbilt University. Dr Morgans treats patients with prostate, bladder, and testicular cancer, and her research assesses complications of advanced prostate cancer survivorship and patient-centered treatment decision-making in advanced prostate cancer.
AAA, Astellas, AstraZeneca, Bayer, Exelixis, Janssen, Myovant, Novartis, Pfizer, Sanofi and Telix.
Two emerging and two established targets
Announcing the publication of survey results
An expert overview of the EMERALD subgroup analysis
Managing patients with nccRCC: guidelines, recommendations, and best practice
Risk factors, diagnostic tools and treatment options for different patient groups
Exploring emerging treatment strategies presented at SABCS 2024